Shire, GlaxoSmithKline sales and marketing update

Shire disclosed in its 3Q10 earnings that during the quarter it terminated a 2009 co-promotion deal with GlaxoSmithKline for Vyvanse lisdexamfetamine in the U.S. to treat ADHD in adults. Shire said t...